PharmacoEconomics

A Simulation Model for Estimating Direct Costs of Type 1 Diabetes Prevention
pp. 295-303(9)
Authors: Hahl J.; Simell T.; Kupila A.; Keskinen P.; Knip M.; Ilonen J.; Simell O.

Cost Effectiveness of Alendronate (Fosamax^®) for the Treatment of Osteoporosis and Prevention of Fractures
pp. 305-314(10)
Authors: Johnell O.; Jönsson B.; Jönsson L.; Black D.

The Cost Effectiveness of Two New Antiepileptic Therapies in the Absence of Direct Comparative Data: A First Approximation
pp. 315-326(12)
Authors: van Hout B.A.; Gagnon D.D.; Mcnulty P.; O'Hagan A.

Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease
pp. 327-340(14)
Authors: Wimo A.; Winblad B.; Stoffler A.; Wirth Y.; Mobius H.

Peginterferon -2a (40kD) [Pegasys^®] Improves HR-QOL Outcomes Compared with Unmodified Interferon -2a [Roferon^®-A]: In Patients with Chronic Hepatitis C
pp. 341-349(9)
Authors: Rasenack J.; Zeuzem S.; Feinman S.V.; Heathcote E.J.; Manns M.; Yoshida E.M.; Swain M.G.; Gane E.; Diago M.; Revicki D.A.; Lin A.; Wintfeld N.; Green J.

Cost Effectiveness of Nasal Budesonide versus Surgical Treatment for Nasal Polyps
pp. 351-356(6)
Authors: Berggren F.; Johansson L.

Factors Affecting UK Primary-Care Costs of Managing Patients with Asthma over 5 Years
pp. 357-369(13)
Authors: Gupta R.D.; Guest J.F.